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In the present issue of Breast Cancer Research, we are
launching a new feature focused on clinical research in
breast cancer. Each issue will contain an update from one
of the major worldwide groups that focuses on their most
important clinical trials. The objectives and scientific
rationale for the trial(s) will be described, and the status of
the trial(s) (present accrual, planned closure date) will also
be provided. We are pleased that the European
Organisation for Research and Treatment of Cancer
(Belgium) was willing to be the first in this series.
We have two goals in mind in promoting this new feature.
First, we want to provide a forum for each of the
cooperative groups to share their current research. In this
way, clinicians and researchers around the world can
become familiar with the questions that are being
addressed in ongoing trials. These updates may, in some
cases, lead to collaborations across groups. The recent
and ongoing experience with the trials in premenopausal
women with hormone receptor-positive tumors has
demonstrated the feasibility of conducting clinical trials
(SOFT, A Phase III Trial Evaluating the Role of Ovarian
Function Suppression and the Role of Exemestane as
Adjuvant Therapies for Premenopausal Women with
Endocrine Responsive Breast Cancer; TEXT, A Phase III
Trial Evaluating the Role of Exemestane Plus GnRH
Analogue as Adjuvant Therapy for Premenopausal Women
with Endocrine Responsive Breast Cancer; and PERCHE,
A Phase III Trial Evaluating the Role of Chemotherapy as
Adjuvant Therapy for Premenopausal Women with
Endocrine Responsive Breast Cancer Who Receive
Endocrine Therapy ) on both sides of the Atlantic Ocean.
Furthermore, we hope these clinical trial updates may lead
to enhanced patient accrual through awareness and
referrals.
The second goal is even more important. Despite
improvements in breast cancer screening, local therapy,
and adjuvant systemic therapy, far too many women
ultimately die from breast cancer. Over the past decade,
there has been an unprecedented expansion in our
understanding of the basic mechanisms underlying breast
cancer. There is greater knowledge than ever before about
growth factor receptors, signaling pathways, tumor–
stromal interactions, and a whole range of other topics
that could lead to therapeutic advances. It is our view that
a substantial reduction in breast cancer mortality is
critically dependent on close collaborations between
basic, translational, and clinical researchers. By publishing
updates of the ongoing trials, we hope to bring basic and
translational scientists who work on breast cancer closer
to the clinic by exposing them to the unanswered clinical
questions. At the same time, we challenge clinicians and
clinical trialists to interact with their colleagues in the
laboratory and to design trials that will help answer
questions that arise from laboratory-based hypotheses.
At some point in the not so distant future, mortality from
breast cancer will be a concept of the past. But
approaching this goal in the next decade will depend upon
close and thoughtful collaborations between those of us
who see patients and design trials, and our colleagues
who are working in the laboratory.
We hope the series will be of interest to the readership of
Breast Cancer Research. Over the months ahead, we
welcome and look forward to your comments on how we
can improve this effort.
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